VYGR Voyager Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VYGR

Price (delayed)

$2.87

Market cap

$176.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.81

Enterprise value

$170.91M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 31

Voyager Therapeutics, Inc. is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes ...

Highlights
The company's debt fell by 19% YoY and by 6% QoQ
Voyager Therapeutics's EPS has increased by 9% from the previous quarter and by 2.7% YoY
Voyager Therapeutics's quick ratio has increased by 39% YoY but it has decreased by 12% from the previous quarter
VYGR's equity is down by 37% year-on-year and by 11% since the previous quarter
VYGR's gross profit is down by 19% year-on-year and by 6% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.voyagertherapeutics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of VYGR

VYGR stock price

How has the Voyager Therapeutics stock price performed over time
Intraday
-8.6%
1 week
-5.9%
1 month
-15.34%
1 year
-30%
YTD
-26.97%
QTD
-18%

Financial performance

How have Voyager Therapeutics's revenue and profit performed over time
Revenue
$34.46M
Gross profit
$34.46M
Operating income
-$117.19M
Net income
-$107.73M
Gross margin
100%
Net margin
-312.6%
The company's net margin fell by 23% YoY but it rose by 2.2% QoQ
VYGR's gross profit is down by 19% year-on-year and by 6% since the previous quarter
The revenue is down by 19% year-on-year and by 6% since the previous quarter
The operating margin has contracted by 17% YoY but it has grown by 2.6% from the previous quarter

Price vs fundamentals

How does VYGR's price correlate with its fundamentals

Growth

What is Voyager Therapeutics's growth rate over time

Valuation

What is Voyager Therapeutics stock price valuation
VYGR P/E details
P/E
N/A
P/B
1.12
P/S
5.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.96
Voyager Therapeutics's EPS has increased by 9% from the previous quarter and by 2.7% YoY
VYGR's equity is down by 37% year-on-year and by 11% since the previous quarter
VYGR's price to book (P/B) is 32% lower than its 5-year quarterly average of 1.8 but 2.5% higher than its last 4 quarters average of 1.2
VYGR's price to sales (P/S) is 23% more than its 5-year quarterly average of 4.5 but 18% less than its last 4 quarters average of 6.7
The revenue is down by 19% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Voyager Therapeutics business performance
Voyager Therapeutics's return on assets has shrunk by 56% YoY and by 4.4% QoQ
VYGR's return on equity has dropped by 54% year-on-year and by 3.4% since the previous quarter
Voyager Therapeutics's ROIC has decreased by 42% YoY and by 3.7% from the previous quarter
Voyager Therapeutics's ROS has decreased by 24% YoY but it has increased by 2.2% from the previous quarter

Dividends

What is VYGR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VYGR.

Financial health

How did Voyager Therapeutics financials performed over time
The total liabilities has contracted by 45% YoY and by 5% from the previous quarter
Voyager Therapeutics's quick ratio has increased by 39% YoY but it has decreased by 12% from the previous quarter
The company's debt is 79% lower than its equity
VYGR's equity is down by 37% year-on-year and by 11% since the previous quarter
VYGR's debt to equity is up by 31% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.